Effects of Insulin Intensification on FINS, CP, HOMA-IR, and HbA1c Levels in Patients with Gestational Diabetes Mellitus
Effects of Insulin Intensification on FINS, CP, HOMA-IR, and HbA1c Levels in Patients with Gestational Diabetes Mellitus
Qian Liu*, Minhuan Sun and Zijuan Xu
ABSTRACT
The objective of this study was to evaluate the effects of insulin combined with metformin on glycemic control and fasting insulin (FINS), C-peptide (CP), homeostasis model assessment of insulin resistance (HOMA-IR) and glycated hemoglobin (HbA1c) levels in patients with gestational diabetes mellitus (GDM). Eighty-eight GDM patients from January 2020 to December 2022 were picked as study subjects and stochastically put into a control group (CG) and an observation group (OG). The OG received combined therapy, while the CG received single metformin therapy. The time to achieve fasting plasma glucose (FPG) target, 2-h postprandial plasma glucose (2hPG) target, and both FPG and 2hPG targets were recorded. FINS, CP, HOMA-IR, and HbA1c levels were also monitored and recorded. The time to achieve FPG target, 2hPG target, and both FPG and 2hPG targets in the OG were significantly lower than those in the CG (P<0.05). After treatment, the FINS, CP, HOMA-IR, and HbA1c levels in the OG were lower than the other’s value (P<0.05). Additionally, the incidence of adverse maternal and neonatal outcomes in the OG was significantly lower than the other’s value (P<0.05). Combined therapy had a significant glycemic control effect in GDM. The blood glucose control in the OG is superior to that in the CG, as evidenced by shorter time to achieve targets and decreased FINS, CP, HOMA-IR, and HbA1c levels. Therefore, insulin combined with metformin has an important clinical efficacy in GDM management, as it improves blood glucose control, reduces the occurrence of adverse outcomes, and provides effective treatment strategies for GDM patients.
To share on other social networks, click on any share button. What are these?
